209 related articles for article (PubMed ID: 31234917)
1. ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals.
Huang CP; Chen J; Chen CC; Liu G; Zhang Y; Messing E; Yeh S; Chang C
J Exp Clin Cancer Res; 2019 Jun; 38(1):275. PubMed ID: 31234917
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor (AR) degradation enhancer ASC-J9
Cheng MA; Chou FJ; Wang K; Yang R; Ding J; Zhang Q; Li G; Yeh S; Xu D; Chang C
Cancer Lett; 2018 Mar; 417():182-191. PubMed ID: 29203251
[TBL] [Abstract][Full Text] [Related]
3. Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression.
Shang Z; Li Y; Zhang M; Tian J; Han R; Shyr CR; Messing E; Yeh S; Niu Y; Chang C
Mol Cancer Ther; 2015 Nov; 14(11):2586-94. PubMed ID: 26264279
[TBL] [Abstract][Full Text] [Related]
4. Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression.
Chou FJ; Chen Y; Chen D; Niu Y; Li G; Keng P; Yeh S; Chang C
EBioMedicine; 2019 Feb; 40():504-516. PubMed ID: 30692044
[TBL] [Abstract][Full Text] [Related]
5. ASC-J9
Lin W; Luo J; Sun Y; Lin C; Li G; Niu Y; Chang C
Cancer Lett; 2018 Jul; 425():21-30. PubMed ID: 29425687
[TBL] [Abstract][Full Text] [Related]
6. Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression.
Luo J; Tian J; Chou F; Lin C; Xing EZ; Zuo L; Niu Y; Yeh S; Chang C
Cancer Lett; 2019 Mar; 444():35-44. PubMed ID: 30248372
[TBL] [Abstract][Full Text] [Related]
7. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
[TBL] [Abstract][Full Text] [Related]
8. ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling.
Tian H; Chou FJ; Tian J; Zhang Y; You B; Huang CP; Yeh S; Niu Y; Chang C
J Exp Clin Cancer Res; 2021 Jan; 40(1):3. PubMed ID: 33390173
[TBL] [Abstract][Full Text] [Related]
9. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.
Yamashita S; Lai KP; Chuang KL; Xu D; Miyamoto H; Tochigi T; Pang ST; Li L; Arai Y; Kung HJ; Yeh S; Chang C
Neoplasia; 2012 Jan; 14(1):74-83. PubMed ID: 22355276
[TBL] [Abstract][Full Text] [Related]
10. ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.
Wen S; Tian J; Niu Y; Li L; Yeh S; Chang C
Cancer Lett; 2016 Jul; 376(2):377-86. PubMed ID: 27045473
[TBL] [Abstract][Full Text] [Related]
11. Combination of androgen receptor inhibitor and cisplatin, an effective treatment strategy for urothelial carcinoma of the bladder.
Tyagi A; Chandrasekaran B; Kolluru V; Rai S; Jordan AC; Houda A; Messer J; Ankem M; Damodaran C; Haddad A
Urol Oncol; 2019 Jul; 37(7):492-502. PubMed ID: 31006613
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer.
Kashiwagi E; Ide H; Inoue S; Kawahara T; Zheng Y; Reis LO; Baras AS; Miyamoto H
Oncotarget; 2016 Aug; 7(31):49169-49179. PubMed ID: 27322140
[TBL] [Abstract][Full Text] [Related]
13. Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor.
Hsu JW; Hsu I; Xu D; Miyamoto H; Liang L; Wu XR; Shyr CR; Chang C
Am J Pathol; 2013 May; 182(5):1811-20. PubMed ID: 23499463
[TBL] [Abstract][Full Text] [Related]
14. A review of the effects and molecular mechanisms of dimethylcurcumin (ASC-J9) on androgen receptor-related diseases.
Hu H; Zhou H; Xu D
Chem Biol Drug Des; 2021 Apr; 97(4):821-835. PubMed ID: 33277796
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib with ASC-J9
Xu J; Lin H; Li G; Sun Y; Shi L; Ma WL; Chen J; Cai X; Chang C
Int J Cancer; 2017 Feb; 140(3):705-717. PubMed ID: 27668844
[TBL] [Abstract][Full Text] [Related]
16. Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells.
Wen S; Niu Y; Lee SO; Yeh S; Shang Z; Gao H; Li Y; Chou F; Chang C
Mol Carcinog; 2016 Dec; 55(12):2278-2290. PubMed ID: 26894509
[TBL] [Abstract][Full Text] [Related]
17. Nuclear Factor-κB Promotes Urothelial Tumorigenesis and Cancer Progression via Cooperation with Androgen Receptor Signaling.
Inoue S; Ide H; Mizushima T; Jiang G; Netto GJ; Gotoh M; Miyamoto H
Mol Cancer Ther; 2018 Jun; 17(6):1303-1314. PubMed ID: 29592878
[TBL] [Abstract][Full Text] [Related]
18. Determination of androgen receptor degradation enhancer ASC-J9(®) in mouse sera and organs with liquid chromatography tandem mass spectrometry.
Soh SF; Huang CK; Lee SO; Xu D; Yeh S; Li J; Yong EL; Gong Y; Chang C
J Pharm Biomed Anal; 2014 Jan; 88():117-22. PubMed ID: 24042123
[TBL] [Abstract][Full Text] [Related]
19. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor.
Yang Z; Chang YJ; Yu IC; Yeh S; Wu CC; Miyamoto H; Merry DE; Sobue G; Chen LM; Chang SS; Chang C
Nat Med; 2007 Mar; 13(3):348-53. PubMed ID: 17334372
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
Shi L; Lin H; Li G; Sun Y; Shen J; Xu J; Lin C; Yeh S; Cai X; Chang C
Cancer Lett; 2016 Apr; 373(1):45-56. PubMed ID: 26805759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]